The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients

Published:2023-07-24 Issue:37 Volume:44 Page:3492-3494
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

DeVries J Hans¹²^ORCID,Irs Alar³^ORCID,Hillege Hans L⁴^ORCID

Affiliation:

1. Seconded National Expert, European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS Amsterdam, the Netherlands

2. Department of Internal Medicine , Amsterdam UMC, Locatie AMC, Meibergdreef 9, 1105 AZ Amsterdam , the Netherlands

3. CHMP member, State Agency of Medicines , Tartu , Estonia

4. CHMP member, Medicines Evaluation Board , Utrecht , the Netherlands

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

https://academic.oup.com/eurheartj/article-pdf/44/37/3492/51823692/ehad429.pdf

Reference7 articles.

1. Factors influencing long-term heart failure mortality in patients with obstructive hypertrophic cardiomyopathy in Western Sweden: probable dose-related protection from beta-blocker therapy;Javidgonbadi;Open Heart,2019

2. CYP2C19 Allele frequencies in over 2.2 million direct-to-consumer genetics research participants and the potential implication for prescriptions in a large health system;Ionova;Clin Transl Sci,2020

3. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial;Olivotto;Lancet,2020

4. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy;Desai;J Am Coll Cardiol,2022

5. ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines;Gersh;Circulation,2011

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Real‑World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten;American Journal of Cardiovascular Drugs;2024-08-21

2. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM;Journal of the American Heart Association;2024-08-06

3. Comentarios a la guía ESC 2023 sobre el tratamiento de las miocardiopatías;Revista Española de Cardiología;2024-04

4. Comment on: European Heart Journal global spotlight on European Medicines Agency evaluation of mavacamten;European Heart Journal Open;2024-03-01

5. A Multicenter Evaluation of the Impact of Therapies on Deep Learning-based Electrocardiographic Hypertrophic Cardiomyopathy Markers;2024-01-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3